| |
| |
|
| Insider
Information: |
Starr Kevin P |
| Relationship: |
10% Owner |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
12 |
|
| Direct
Shares |
12,946,933 |
|
|
Indirect Shares
|
23,291,181 |
|
|
| Direct
Value |
$331,905,965 |
|
|
|
Indirect Value
|
$1,128,014,200 |
|
|
| Total
Shares |
36,238,114 |
|
|
| Total
Value |
$1,459,920,165 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 53.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Human Genome Sciences Inc |
HGSI |
Director |
2007-07-10 |
695 |
2007-07-10 |
0 |
Premium* |
|
|
Alnylam Pharmaceuticals Inc |
ALNY |
Director |
2015-11-12 |
0 |
2013-03-25 |
0 |
Premium* |
|
|
Agios Pharmaceuticals Inc |
AGIO |
Director, 10% Owner |
2015-02-19 |
184,386 |
2015-02-19 |
0 |
Premium* |
|
|
Larimar Therapeutics Inc |
LRMR |
Director |
2015-09-24 |
370,323 |
2015-09-24 |
0 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
|
2021-06-16 |
320,659 |
2019-02-12 |
0 |
Premium* |
|
|
Global Blood Therapeutics, Inc. |
GBT |
10% Owner |
2017-06-14 |
3,165,624 |
2016-12-16 |
8,760,904 |
Premium* |
|
|
Editas Medicine, Inc. |
EDIT |
10% Owner |
2016-09-06 |
0 |
2016-09-06 |
3,906,176 |
Premium* |
|
|
Blueprint Medicines Corp |
BPMC |
10% Owner |
2016-12-19 |
0 |
2016-12-19 |
5,453,753 |
Premium* |
|
|
Jounce Therapeutics Inc |
JNCE |
10% Owner |
2017-02-01 |
3,048,780 |
2017-02-01 |
0 |
Premium* |
|
|
Cytomx Therapeutics, Inc. |
CTMX |
10% Owner |
2017-04-12 |
31,419 |
2017-04-12 |
5,170,348 |
Premium* |
|
|
Allena Pharmaceuticals, Inc. |
ALNA |
10% Owner |
2017-11-06 |
2,790,964 |
2017-11-06 |
0 |
Premium* |
|
|
Constellation Pharmaceuticals Inc |
CNST |
10% Owner |
2018-08-22 |
3,034,083 |
2018-07-23 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SAGE |
Sage Therapeutics, Inc. |
|
– • – |
2021-06-16 |
4 |
B |
$56.05 |
$999,983 |
D/D |
17,842 |
320,659 |
0.01 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • – |
2019-02-12 |
4 |
S |
$0.00 |
$0 |
I/I |
(0) |
0 |
0 |
- |
|
| CNST |
Constellation Pharmaceuti... |
10% Owner |
– – • |
2018-08-22 |
4 |
OE |
$1.55 |
$79,100 |
D/D |
51,032 |
3,034,083 |
0 |
- |
|
| CNST |
Constellation Pharmaceuti... |
10% Owner |
– – • |
2018-07-23 |
4 |
B |
$15.00 |
$4,000,005 |
D/D |
266,667 |
2,983,051 |
2.45 |
- |
|
| CNST |
Constellation Pharmaceuti... |
10% Owner |
– – • |
2018-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,705,334 |
2,716,384 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • – |
2018-04-18 |
4 |
S |
$168.28 |
$4,038,650 |
D/D |
(24,000) |
302,817 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • – |
2018-04-17 |
4 |
S |
$169.25 |
$5,923,600 |
D/D |
(35,000) |
326,817 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • – |
2018-02-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(510,554) |
37,362 |
0 |
- |
|
| ALNA |
Allena Pharmaceuticals, I... |
10% Owner |
– – • |
2017-11-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,575,964 |
2,575,964 |
0 |
- |
|
| ALNA |
Allena Pharmaceuticals, I... |
10% Owner |
– – • |
2017-11-06 |
4 |
B |
$14.00 |
$3,010,000 |
D/D |
215,000 |
2,790,964 |
2.45 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • – |
2017-09-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(545,000) |
547,916 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • – |
2017-07-18 |
4 |
AS |
$0.00 |
$0 |
I/I |
(800,000) |
1,092,916 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
10% Owner |
– – • |
2017-06-14 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,000,000) |
2,475,191 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
10% Owner |
– – • |
2017-05-17 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,000,000) |
3,475,191 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
10% Owner |
– – • |
2017-04-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,708 |
163,996 |
0 |
- |
|
| CTMX |
Cytomx Therapeutics, Inc. |
10% Owner |
– – • |
2017-04-12 |
4 |
S |
$16.36 |
$463,793 |
D/D |
(28,357) |
31,419 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
10% Owner |
– – • |
2017-04-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
50,000 |
165,704 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
10% Owner |
– – • |
2017-04-06 |
4 |
AS |
$0.00 |
$0 |
D/D |
(2,000,000) |
4,475,191 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
10% Owner |
– – • |
2017-03-02 |
4 |
S |
$25.50 |
$52,245,476 |
D/D |
(2,045,294) |
146,208 |
0 |
- |
|
| JNCE |
Jounce Therapeutics Inc |
10% Owner |
– – • |
2017-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,737,124 |
3,048,780 |
0 |
- |
|
| JNCE |
Jounce Therapeutics Inc |
10% Owner |
– – • |
2017-01-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
542,005 |
|
- |
|
| SAGE |
Sage Therapeutics, Inc. |
Director |
– • – |
2017-01-23 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,000,000) |
1,892,916 |
0 |
- |
|
| BPMC |
Blueprint Medicines Corp |
10% Owner |
– – • |
2016-12-19 |
4 |
S |
$28.19 |
$3,002,351 |
D/D |
(106,489) |
0 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
10% Owner |
– – • |
2016-12-16 |
4 |
S |
$16.00 |
$1,743,345 |
D/D |
(108,955) |
82,544 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
10% Owner |
– – • |
2016-11-14 |
4 |
S |
$19.36 |
$38,720,000 |
D/D |
(2,000,000) |
1,285,713 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
